Chemoradiotherapy, whether it is given to a cancer patient before (neoadjuvant) or after (adjuvant) surgery to remove a cancer tumor means one thing. Toxicity. Lots of toxicity. And toxicity means side-effects.
The studies linked below do say that chemoradiation before surgery to remove the Esophageal Cancer does improve one’s 5-year survival rate. However, stating that there were “no increased postoperative complications” with EC patients does not mean that these EC patients didn’t experience extreme toxicity. And therefore may experience long-term and late-stage side effects.
There are evidenced-based therapies that are proven to both ENHANCE the efficacy of conventional chemo and radiation while they REDUCE the risk of side effects (reduce toxicity) from conventional chemotherapy and radiation.
To learn more about integrative therapies to both enhance the efficacy of chemotherapy as well as reduce the toxicity of chemo, scroll down the page, post a question or a comment and I will reply to you ASAP.
“The role of neoadjuvant therapy in the treatment of locally advanced EC still remains controversial…
The tumor resection rate, pathological stage, treatment-related complication, and survival among groups were compared. The radical resection rate for the patients in radiotherapy and radiochemotherapy groups was increased in comparison with the control group..”
“BACKGROUND: Many studies have demonstrated that chemoradiotherapy followed by surgery (CRTS) prolongs the 5-year survival rate of resectable esophageal carcinoma patients. However, the effect of CRTS on postoperative complications, local recurrence and distant metastasis remains controversial. We performed a systematic review of the literature and conducted a meta-analysis to assess the postoperative efficacy of CRTS compared with surgery alone (SA).
CONCLUSIONS: CRTS significantly decreased postoperative mortality, local recurrence and distant metastasis rates compared to SA. Additionally, there were no increased postoperative complications for patients with resectable esophageal carcinoma.